40137-11-9

Basic information

• Product Name: Diethyl(methylsulfonylmethyl)phosphonate
• Synonyms: Diethyl(methylsulfonylmethyl)phosphonate
• CAS NO: 40137-11-9
• Molecular Formula: C₆H₁₅O₅PS
• Molecular Weight: 228.203181
• Mol File: 40137-11-9.mol
• Article Data: 20

Chemical Properties

• Melting Point: 93-95°C
• Boiling Point: 373.6°C at 760 mmHg
• Flash Point: 179.7°C
• Appearance: /
• Density: 1.241g/cm³
• Vapor Pressure: 1.91E-05mmHg at 25°C
• Refractive Index: 1.439
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Diethyl(methylsulfonylmethyl)phosphonate(CAS DataBase Reference)
• NIST Chemistry Reference: Diethyl(methylsulfonylmethyl)phosphonate(40137-11-9)
• EPA Substance Registry System: Diethyl(methylsulfonylmethyl)phosphonate(40137-11-9)

Safety Data

• Hazardous Substances Data: 40137-11-9(Hazardous Substances Data)

Usage

General Description

Diethyl(methylsulfonylmethyl)phosphonate is a chemical compound with the molecular formula C7H17O4PS. It is commonly used as an intermediate in the synthesis of pharmaceuticals, herbicides, and insecticides. Diethyl(methylsulfonylmethyl)phosphonate is also used as a substrate in the study of enzymes and other biological processes. It is a colorless, odorless liquid that is insoluble in water but soluble in organic solvents. Diethyl(methylsulfonylmethyl)phosphonate is known to be stable when stored properly, but it should be handled with caution due to its potential to cause irritation to the skin, eyes, and respiratory system.

InChI:InChI=1/C6H15O5PS/c1-4-10-12(7,11-5-2)6-13(3,8)9/h4-6H2,1-3H3

Upstream product

• 28460-01-7 diethyl 1-(methylthio)methylphosphonate 
• 937-14-4 3-chloro-benzenecarboperoxoic acid 
• 87762-57-0 (Methylthio)(trimethylsilyl)methylphosphonsaeure-diethylester 
• 14467-94-8 diethyl <(trimethylsilyl)methyl>phosphonate 
• 3167-63-3 diethyl chloromethylphosphonate 
• 73778-52-6 (Methylsulfanyl-phenylsulfanyl-methyl)-phosphonic acid diethyl ester 
• 62999-70-6 S,S-dimethylthioacetal of diethyl oxomethanephosphonate 
• 122422-71-3 (Methanesulfonyl-trimethylsilanyl-methyl)-phosphonic acid diethyl ester 

Downstream Products

• 69957-47-7 (3-dimethylamino-trans-styryl)-methyl-sulfone 
• 69957-45-5 (E)-1-(2-methanesulfonyl-vinyl)-4-methyl-benzene 
• 69957-46-6 (E)-1-fluoro-4-(2-methanesulfonyl-vinyl)-benzene 
• 69957-43-3 methyl-(3-nitro-trans-styryl)-sulfone 
• 40807-13-4 (E)-1-(4-Nitrophenyl)-2-(methylsulfonyl)-ethen 
• 74267-50-8 1-Methanesulfonylmethylene-4-methyl-cyclohexane 
• 76842-45-0 (E)-1-bromo-4-(2-methanesulfonyl-vinyl)-benzene 
• 5897-46-1 3-methyl-1-(methylsulphonyl)-2-butene 
• 286376-75-8 (E)-3-methyl-1-(methylsulfonyl)-1-butene 
• 69957-44-4 trans-β-(4-Cyano-styryl)-methyl-sulfon 
• 894853-81-7 (2-{(1S,5S)-5-(4-Chloro-benzenesulfonyl)-5-(2,5-difluoro-phenyl)-2-[1-methanesulfonyl-meth-(E)-ylidene]-cyclohexylmethoxy}-ethyl)-trimethyl-silane 

Relevant articles and documents

Steroidal cardiotonics. II. Replacement of the butenolide ring of cardiac glycosides by unbranched open chain π electron systems

-

Selective caspase inhibitors and uses thereof

The present invention relates to compounds of Formula I, IA, II, HA, III, or IHA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).

ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF

Provided herein is a method of preventing, treating, or ameliorating one or more symptoms of an adenosine A3-mediated condition, disorder, or disease, with a compound of Formula I. Also provided herein is a method of preventing, treating, or ameliorating one or more symptoms of glaucoma or ocular hypertension. Further provided herein is a method of modulating the activity of an adenosine A3 receptor.